Axel Dignass, MD, PhD, Agaplesion Markus Hospital, Goethe University, discusses recent findings from the phase 2b QUASAR study, which demonstrated increased clinical remission at 12 weeks with guselkumab compared with placebo for moderate to severe ulcerative colitis. The results demonstrated comparable safety and efficacy of the two doses that were tested (200 and 400 mg IV). No safety signals for guselkumab were observed.

View video by clicking here.